EUCTR2008-001551-22-FR进行中（未招募）1 期
A randomized, double-blind, placebo controlled, multicenter, phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) to first line chemotherapy in patients with optimally debulked ( < 1cm) epithelial ovarian cancer
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Histologically-confirmed optimally debulked (< 1 cm) FIGO stage III or stage IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.
- •- Patients should have undergone surgical debulking, by a surgeon experienced in the management of ovarian cancer, with the aim of maximal surgical cytoreduction. All patients must be optimally debulked as defined as having no residual tumor of greater than 1 cm in the post surgical setting.
- •- Patients with stage IV disease will be eligible if a positive pleural cytology is the only extra peritoneal disease.
- •- Paraffin block (or 10 – 20 unstained slides) and fresh frozen surgical/biopsy specimens of the primary tumor are required at baseline.
- •- No prior systemic treatment in the primary disease treatment setting.
- •- Female > 18 years of age or legal age.
- •- ECOG performance status = 2.
- •- Adequate organ and bone marrow function as evidenced by:
- •- hemoglobin = 9.0 g/dL,
- •- absolute neutrophil count = 1.5 x 109/L,
- •- platelet count = 100 x 109/L,
- •- Serum creatinine = 1.5 x ULN and measured or calculated creatinine clearance = 60 mL/min.
- •- AST and ALT = 2.5 x ULN
- •- total bilirubin = 1.5 x ULN unless increase is due to Gilbert’s disease or similar syndrome involving slow conjugation of bilirubin,
- •- Non diabetic patients or Type 1 or 2 Diabetic Patients:
- •- Diabetes must be controlled with HgbA1c < 8% and fasting blood glucose level <160 mg/dL.
- •- Patient must be willing and able to comply with scheduled visits, and all study procedures.
- •- Informed consent obtained.
- •- Patients should be able to commence systemic therapy within 6 weeks of cytoreductive surgery.
- •- Life expectancy > 12 weeks.
- •- Adequate coagulation parameters (within 14 days prior to randomization), International Normalized Ratio (INR) =1.5; Activated Prothrombin Time (APTT) = 1.5 x ULN.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Non-epithelial ovarian cancer, including malignant mixed Mullerian tumors.
- •- Borderline tumors (tumors of low malignant potential).
- •- Planned intraperitoneal cytotoxic chemotherapy.
- •- Prior systemic anticancer therapy for ovarian cancer.
- •- Any previous radiotherapy to the abdomen or pelvis.
- •- Patients with synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless ALL of the following criteria for describing the endometrial carcinoma are met: Stage = Ib, no more than superficial myometrial invasion, no lymphovascular invasion, not poorly differentiated (i.e., not Grade 3 or papillary serous or clear cell).
- •- Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri.
- •- Prior treatment with a humanized monoclonal antibody anticancer therapeutic.
- •- Prior treatment with investigational treatment targeted to IGF axis including, but not limited to, CP 751,871, IM-A12, RO4858696.
- •- Previous exposure to AMG 479.
- •- Anticipation of a need for a major surgical procedure or radiation therapy during the study.
- •- History of hypersensitivity to recombinant proteins.
- •- Treatment with radiotherapy, surgery, or an investigational agent within 4 weeks of randomization.
- •- Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, cerebrovascular accident or transient ischemic attack, grade = 2 peripheral neuropathy, pulmonary embolism, deep vein thrombosis, or other thromboembolic event.
- •- History of brain metastases, spinal cord compression, or carcinomatous meningitis.
- •- Patient of child-bearing potential is pregnant (eg, positive human chorionic gonadotropin test) or is breast feeding.
- •- Patient of child-bearing potential is not willing to use adequate contraceptive precautions.
- •- Known active infection, or on antiretroviral therapy for HIV disease.
- •- Known positive test for chronic hepatitis B or C infection.
- •- Any other underlying physical or mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.
- •- Refusal or inability to give informed consent to participate in the study.
- •- Other severe acute or chronic medical or psychiatric condition, or significant laboratory abnormality requiring further investigation that may cause undue risk for the patient’s safety, inhibit protocol participation, or interfere with interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study
研究者
相似试验
进行中（未招募）
不适用
Investigation of the impact of Omalizumab on quality of life measures as well as incidence and severity of angioedema in patients with spontaneous urticariamoderate to severe chronic spontaneous urticaria with angioedemaMedDRA version: 14.1Level: LLTClassification code 10009159Term: Chronic urticariaSystem Organ Class: 100000004858EUCTR2011-004254-25-DEovartis Pharma GmbH
进行中（未招募）
1 期
A study to evaluate a combined oral contraceptive (COC) and dehydroepiandrosterone or placebo to treat decreased sexual desire caused by COC use.Hypoactive sexual desire disorder (HSDD) secondary to combined oral contraception use.MedDRA version: 20.0Level: LLTClassification code 10020933Term: Hypoactive sexual desire disorderSystem Organ Class: 100000004873EUCTR2020-000716-30-CZGedeon Richter Plc.512
进行中（未招募）
1 期
Safety and efficacy study in patients with moderate to severe nail psoriasisModerate to severe nail psoriasisMedDRA version: 19.1Level: PTClassification code 10028703Term: Nail psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-005413-40-CZovartis Pharma Services AG195
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, multicentre study to evaluate the effect of a 12-week dose of 35 mg DHEA on quality of life in menopausal women.MenopauseEUCTR2023-000224-10-PLThe Pharmaceutical Company LEK-AM Sp. Zo.o.100
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter, parallel-group, adaptive group-sequential phase II study, to determine the efficacy and safety of BT086 as an adjunctive treatment in severe pneumonia (sCAP) acquired outside the hospitalsevere Community Acquired Pneumonia (sCAP)MedDRA version: 16.0Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 100000004862EUCTR2010-022380-35-GBBiotest AG160